Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications

Journal of Clinical Psychopharmacology

Volumn 32, Issue 3, 2012, Pages 323-328

  Aggarwal, Neil Krishan ^a,b   Sernyak, Michael J ^a,b   Rosenheck, Robert A ^b,c  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA New England Mental Illness Research and Education Center   (United States)

Author keywords

adherence; compliance; decanoate; long acting antipsychotic; schizophrenia

Indexed keywords

ACEBUTOLOL; FLUPHENAZINE; HALOPERIDOL; LONG ACTING DRUG; MICROSPHERE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AFRICAN AMERICAN; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; DEMENTIA; DEPRESSION; DISORIENTATION; DRUG DEPENDENCE; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MEMORY DISORDER; MENTAL PATIENT; MONOTHERAPY; PATIENT COMPLIANCE; PHARMACY; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; CONNECTICUT; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAMUSCULAR; MALE; MEDICAL RECORDS; MENTAL HEALTH SERVICES; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 84861087821     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31825244f6     Document Type: Article

References (27)

1. Driscoll PL. Maintenance medication for chronic schizophrenics: Risk/benefit assessment. Perspect Psychiatr Care. 1985;23:104-110.
2. Johnson DA. Antipsychotic medication: Clinical guidelines for maintenance therapy. J Clin Psychiatry. 1985;46:6-15.
3. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs. 1994;47:741-773.
4. Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: A prospective, 6-month follow-up of 100 patients. J Clin Psychiatry. 2004;65:1076-1083.
5. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33:1379-1387.
6. Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2006;67:1194-1203.
7. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64:1250-1257.
8. Mohamed S, Rosenheck R, Harpaz-Rotem I, et al. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr Q. 2009;80:241-249.
9. Glazer WM, Kane JM. Depot neuroleptic therapy: An underutilized treatment option. J Clin Psychiatry. 1992;53:426-433.
10. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998;8:55-66.
11. Koshino Y. Algorithm for treatment-refractory schizophrenia. Psychiatry Clin Neurosci. 1999;53(suppl):S9-S13.
12. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S63-S67.
13. Masand PS, Gupta S. Long-acting injectable antipsychotics in the elderly: Guidelines for effective use. Drugs Aging. 2003;20:1099-1110.
14. Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: Time to reconsider when to introduce depot antipsychotics. CNS Drugs. 2007;21:441-448.
15. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-299.
16. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl. 2009;52:S20-S28.
17. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophreniaVa critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83-92.
18. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364:842-851.
19. Mukherjee S, Shukla S, Woodle J, et al. Misdiagnosis of schizophrenia in bipolar patients: A multiethnic comparison. Am J Psychiatry. 1983;140(12):1571-1574.
20. Minsky S, Vega W, Miskimen T, et al. Diagnostic patterns in Latino, African American, and European American psychiatric patients. Arch Gen Psychiatry. 2003;60(6):637-644.
21. Chen YR, Swann AC, Burt DB. Stability of diagnosis in schizophrenia. Am J Psychiatry. 1996;153:682-686.
22. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists. Psychiatry Res. 2010;175:58-62.
23. Patel MX, de Zoysa N, Bernadt M, et al. Are depot antipsychotics more coercive than tablets? The patient's perspective. J Psychopharmacol. 2010;24:1483-1489.
24. Patel MX, de Zoysa N, Bernadt M, et al. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: Depot versus oral. J Clin Psychiatry. 2008;69:1548-1456.
25. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: Systematic review. Br J Psychiatry Suppl. 2009;52:S43-S50.
26. Patel MX, De Zoysa N, Bernadt M, et al. Depot and oral antipsychotics: Patient preferences and attitudes are not the same thing. J Psychopharmacol. 2009;23:789-796.
27. Velligan DI, Medellin E, Draper M, et al. Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J. 2011;47(6): 654-659.